2012 Annual Meeting in Tampa, FL, April 29-May 2
Pre-Meeting Workshop: MTM Boot Camp The Business of Patient Care: Incorporating Comprehensive Medication Management (MTM) into your Practice
Where do you “fit” in the new health care system as a neuropsychiatric pharmacist? This day-long workshop will begin with an update on the health care system. The emphasis will be on the role of the pharmacist in the new organizational structures of the medical home and accountable care organizations.
The program will then demonstrate what payers want from pharmacists who wish to provide medication management services. Keys to defining your service, recruiting patients, demonstrating your value, charging for your services and expanding your service will all be demonstrated.
This workshop will provide critical information to pharmacists in all practice settings. You will get important questions answered and understand what changes are needed to achieve and maintain a successful practice. You will also have the opportunity to learn from individuals in the private sector who have experience in delivering medication management services. Join us with the goal of making your service even more successful in 2012.
CPNP University Online Courses
Programming Available for Nurses
If you have an account with CPNP.org, please log in before attempting to register. By logging in, the system can help you make informed selections based on credits currently on your transcript.
| Active Dates | Title | ACPE Contact Hours | Register |
|---|---|---|---|
| 05/02/2011 - 05/02/2014 |
Seizing the MTM Opportunity: What Psychiatric Pharmacists Need to Know
This presentation will focus on how the health care system is changing and how psychiatric pharmacists need to adapt to these changes to be successful. The objectives for the presentation will be to; a) understand the changing environment, b) adopt terminology that has currency in the new system, c) understand the new rules and regulations, d) be able to recognize success under the new rules, and e) decide which direction for the future is best. The specific changes that impact psychiatric pharmacists will be presented and the consequences of these changes discussed. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 01/29/2010 - 06/30/2012 |
2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care. |
20.0 |
Registration closed. |
| 01/23/2012 - 01/23/2015 |
2012-2013 Psychiatric Pharmacy Review Course - ACPE Credit Only
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care. |
0.0 | Course is not configured. |
| 05/04/2011 - 05/04/2014 |
The FDA: Inside the Black Box-A Discussion of Regulations and Recent Decisions
The Federal Food Drug and Cosmetic act states that approval of a drug requires “substantial evidence” from “adequate and well-controlled investigations”. The Code of Federal Regulations (CFR) codifies the FD&C Act and provides more details regarding what are considered to be adequate and well-controlled investigations. Guidance documents were developed to provide more detailed information, many times specific to the indications being studied, on various topics including clinical trial designs. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Aggression in Children and Adolescents
Children and adolescents with psychiatric disorders may exhibit pathologic aggression that may be destructive, severe, chronic, and unresponsive to psychosocial/ psychopharmacological treatment of their underlying pathology as well as to psychosocial interventions specifically targeting aggression. For this subset of aggressive youth, targeted pharmacotherapy may be appropriate. Evidence is growing to support the use of medications to manage aggressive behaviors across various childhood and adolescent psychiatric disorders. Safety should be emphasized when prescribing medication for these patients. However, serious health and safety risks are also raised when aggression is not effectively managed. This session will review the etiology, phenomenology, and treatment modalities for aggression in children and adolescents, and invoke discussion on best practices to clinically manage aggression in this population. The discussion will highlight evidence-based interventions and expert consensus recommendations, both pharmacologic and nonpharmacologic, and their relative effectiveness. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Emerging Therapies for Multiple Sclerosis
This session reviews new knowledge in the pathophysiology of multiple sclerosis (MS) and describes how this knowledge informs drug therapy development for both immunomodulatory and symptomatic treatment. Great strides in knowledge of MS pathophysiology have occurred over the last decade. The role of B and T cells, other immune cells and tissues, and neurodegeneration are described. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Incorporating Health Services Research: Explaining Conceptual Frameworks Used by Researchers
Health services research involves the study of the impact of health care organization, financing, and delivery on access, quality, outcomes and costs of patient care. It is a multidisciplinary field that employs a wide range of research methods that come from disciplines including but not limited to clinical epidemiology, sociology, economics, and organizational psychology. Still, what brings many of these disciplines together is the application of a common framework towards improving quality of care and reducing disparities in health outcomes. The objectives of this presentation is to describe some of the more common conceptual frameworks used by health services researchers, focusing in particular on emerging frameworks that have been applied to the field of mental health services research, and how clinical and administrative data can be used to address unanswered questions based on these frameworks. The presentation will provide a roadmap for applying the Health Disparities Framework in detecting, understanding, and intervening on gaps in medical outcomes among patients with mental disorders. In addition, the presentation will describe the application of the Replicating Effective Programs framework to implementing patient-centered and psychosocial interventions to reduce disparities in mental disorders, as well as discuss the application of the emerging field of implementation science in facilitating the uptake of evidence-based practices for patients with mental disorders. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Incorporating Health Services Research: Impact, Tools and the Future
The value of Health Services Research (HSR) extends far beyond opportunities for publication and advancement among academicians. Once an infrastructure for conducting HSR has been constructed, psychiatric pharmacists can use measured outcomes to directly influence patient care, justify clinical services, and ultimately advance the profession. One of the best examples of the role HSR may serve in expanding psychiatric pharmacy practice can be found in the area of depression. Over the past decade there has been a determined research focus placed upon systematic efforts to improve the outcomes of depressed patients, including educational campaigns, web-based monitoring and collaborative care arrangements. Several investigations aimed at improving outcomes have featured psychiatric pharmacists in pivotal roles. While the results of these HSR efforts have generally been favorable, the scientific rigor of these investigations has varied considerably and the translation of these findings into practice has not been forthcoming. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Irritability and Elation: The Consequences of Thinking about Pediatric Bipolar Disorder and Sever Mood Dysregulation
Severe mood dysregulation (SMD) is a relatively common childhood syndrome characterized by three features: chronic anger and irritability, recurrent explosive outbursts, and the non-specific hyperarousal symptoms from the “B criteria” for mania including insomnia, agitation, distractibility, pressured speech, racing thoughts, and intrusiveness. Initially, SMD was proposed as an attempt to operationalize a definition of the “broad phenotype” of pediatric bipolar disorder (BD). In an effort to test the assumption that SMD is a developmental form of BD, we examined the clinical course, family history, and neurobiology of individuals with SMD and compared them to pediatric patients with strictly defined DSM-IV BD. Current evidence to guide the pharmacologic treatment of SMD is extremely limited. Patients with SMD may benefit from targeting symptoms or features such as depression, anxiety, and attention-deficit/hyperactivity disorder, but more research is needed on pharmacologic and psychotherapeutic approaches to treatment. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/03/2011 - 05/03/2014 |
Seizures and Psychiatry
During the past few years, the comorbidity of affective disorders and epilepsy has been “re-discovered”. This comorbidity has implications not only in antiepileptic drug (AED) selection, may also shed insight into the pathophysiology of this disorder. This presentation will discuss current treatment choices for various seizure disorders, along with a brief discussion regarding common psychiatric uses of various marketed AED. Common pathophysiological mechanisms of epilepsy and depression will be discussed, as well as an update on current perspectives regarding suicide risk with AEDs. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/02/2011 - 05/02/2014 |
Drug Transporters and Psychiatry
Drug transporters, especially P-glycoprotein, play an important role in drug delivery. During this presentation, basic pharmacokinetic concepts are reviewed. Then, the discussion on drug transporters and p-glycoprotein begins. This discussion will address therapeutic implications in clinical practice of drug transporters along with literature regarding this topic. The presentation will conclude with a summation of the topics discussed and audience participation. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/02/2011 - 05/02/2014 |
Impact of Psychotropic Medications on Sleep Architecture
Sleep, a universal feature of complex organisms, is regulated through the influence of numerous neuromodulatory pathways. This presentation will provide an overview of sleep physiology, architecture, and physiological variability of sleep. The relationship between changes in sleep architecture and the subjective complaints of patients will be discussed, as well as the impact of psychiatric and neurological illness on sleep architecture in drug-naïve patients. The impact of psychotropic medications on sleep architecture will be reviewed class-by-class. Case vignettes will be evaluated to apply the content and illustrate the clinical relevance of the complex relationship of sleep and treatment of psychiatric illness. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/02/2011 - 05/01/2014 |
Medico-Legal Considerations in the Management of Behavioral Disturbances in the Elderly
This presentation will provide participants an overview of the medico-legal considerations regarding treatment of neuropsychiatric symptoms in patients with dementia. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/02/2011 - 05/01/2014 |
Pharmacological Management of Behavioral Disturbances in the Elderly
This presentation will provide participants an overview of the current evidence regarding treatment of neuropsychiatric symptoms in patients with dementia. The presentation will follow the recommendations from the American College of Neuropsychopharmacology (ACNP) white paper. Before initiating treatment for behavioral symptoms in patients with dementia, differential diagnosis is necessary. Once other causes of the behavior are ruled out, nonpharmacologic treatments should be initiated before starting pharmacologic treatment. Several nonpharmacologic treatments and literature supporting efficacy will be discussed. Finally drug therapy will be discussed focusing on antipsychotic medications, adverse effects, and the results of the CATIE-AD trial. During this presentation the audience will have several opportunities to interact and participate in discussions of case presentations using Poll Everywhere technology. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/02/2011 - 05/02/2014 |
Use of Omega-3 Fatty Acids in Mental Illness
Omega-3 fatty acids are involved in many physiologic processes. Since they cannot be made de novo in the body, they are considered essential nutrients and are divided into two groups 1) short chain, alpha linolenic acid (ALA) and 2) long chain, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fatty acids. The long chain omega-3 fatty acids are derived from marine sources such as oily fish and are more frequently implicated in mental illness than ALA. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/01/2011 - 05/01/2014 |
Fibromyalgia: Pain and the Brain
This presentation will discuss the prevalence, clinical presentation, pathophysiology diagnosis and treatment of fibromyalgia syndrome (FMS). While not completely understood, disordered central pain processing likely plays a role in the pathogenesis of FMS and treatment strategies primarily focus on alleviating pain and addressing associated symptoms and comorbid conditions. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/01/2011 - 05/01/2014 |
Putting the Action in Long-Acting Antipsychotic Injections
Since the development and introduction of the long-acting antipsychotic medications in the 1960’s, clinical debates have occurred among health-care providers as to when these medications are appropriate to use. The impact of poor medication adherence among patients with psychiatric disorders has a great impact on their clinical outcomes. Long-acting injectable antipsychotics have been shown to reduce hospitalizations and to improve medication adherence. The clinical pharmacologic properties, safety and tolerability profiles of these medications vary between agents. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 05/01/2011 - 05/01/2014 |
The Role of Antidepressants in Bipolar Disorder: Myth vs. Reality
The safety and efficacy of antidepressants for patients with bipolar disorder continues to remain a source of tremendous controversy. Initial reports of antidepressant-induced mania or hypomania led to marked concern among practitioners that antidepressants were highly likely to destabilize mood and worsen the course of illness in most people with bipolar disorder. More recent investigations indicate that the potential for antidepressants to cause mania or hypomania is a rarer phenomenon than originally thought, occurring in about 10-15% of bipolar disorder patients. Moreover, studies from the past two decades identify patient-specific risk factors for the emergence of antidepressant-associated mania or hypomania, suggesting its potential significance as an illness endophenotype. Clinical studies suggest that the risk for mood destabilization from antidepressants appears higher in individuals with bipolar I (rather than bipolar II) disorder, as well as those with concomitant manic/hypomanic symptoms during depressive illness phases, recent manic or hypomanic episodes, comorbid alcohol or drug abuse, and past histories of antidepressant-induced mood destabilization. Furthermore, risk may be somewhat higher with noradrenergic antidepressants (such as tricyclics or serotonin/norepinephrine reuptake inhibitors) than with purely serotonergic or primarily dopaminergic agents. Co-therapy with antimanic drugs such as lithium may not reliably mitigate the risk for antidepressant-induced mania or hypomania. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/21/2010 - 04/21/2013 |
Strategies to Develop Disease Modifying Drugs: Focus on Alzheimer’s and Surrogate Endpoints
Delve into a discussion of leading biosurrogate markers in the area of Alzheimer’s Disease (AD). The discussion includes a review of the current state of the art for disease modifying drugs, a review of research design methodology as it relates to AD and case illustrations for early drug development as targets for the therapeutics of AD. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/21/2010 - 04/21/2013 |
Treatment of Cognitive Impairment in Schizophrenia
Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with deficits in cognitive functioning. Cognitive enhancement has been proposed as a pathway to disability reduction. This pathway has been clearly defined in terms of the required clinical trials methods, with primary (cognitive) and secondary (functional) outcome measures well validated. Second generation (Newer, Atypical) antipsychotic medications have been thoroughly evaluated with their cognitive enhancement potential. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2010 - 04/20/2013 |
Efficacy vs. Adverse Effects: Which Trumps? Point-Counterpoint
Although first generation antipsychotics (FGAs) provided the bedrock of clinical treatment for people with schizophrenia for over 30 years, the advent of successive new drugs- second generation antipsychotics (SGAs)- led to a decline in use of FGAs in favor of SGAs that were (at least initially) perceived as both more efficacious and better tolerated. While the relative merits of FGAs and SGAs remain hotly debated, it is now clear that the selection of an appropriate antipsychotic for any given patient represents a highly complex clinical decision-making process. |
2.0 |
Non-member rate: $50.00Member rate: $40.00, login |
| 04/20/2010 - 04/20/2013 |
Genetic Epidemiology of Early-Onset Depression and Alcohol Use Disorders
Alcohol-related deaths are the leading cause of mortality in adolescents. Unfortunately alcohol-use disorders (AUD) are also the most prevalent of the substance-use disorders in adolescents and less than 10% of the numbers of adolescents who meet criteria for alcohol treatment actually receive treatment. Current treatments for adolescent AUD are primarily non-pharmacologic. However, recent genetic epidemiology research suggests the combined role of genes and environment in adolescent AUD. Furthermore, Research in the role of stress response suggests emerging targets for pharmacologic interventions. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2010 - 04/20/2013 |
Management of Psychiatric Illness in HIV Patients: A Major Treatment Dilemma
Over 1 million people are living with HIV in the United States. Transmission is on the rise in women, Blacks, Hispanics, heterosexuals, adolescents and elderly. People with human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome have high rates of psychiatric illness. The effective management of these psychiatric conditions can improve a patient's quality of life and may improve antiretroviral adherence. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2010 - 04/19/2013 |
Improving Outcomes in Patients with Traumatic Brain Injury
Traumatic brain injury (TBI) is a significant health problem in the United States, and a frequent cause of disability in young individuals. The Wars in Iraq and Afghanistan have heightened the public awareness of this condition and resulted in an increasing number of individuals presenting for treatment due to concern of a suspected TBI. In order to best manage the sequelae of TBI, providers must understand important prognostic factors which impact clinical outcome including injury severity and co-morbid conditions. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2010 - 04/19/2013 |
Life After Star*D: Lessons Learned and the Next Steps for Managing Depression
Major depression is a complex disorder, with as many as 50% of patients non-responsive to initial antidepressant therapy. The NIMH sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) set out to determine what the next “best step” was for patients not responding adequately to one or more prior treatments. In addition, given the large, representative patient sample and comprehensive data collected, STAR*D was able to provide clinical and genetic predictors of treatment outcomes. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2010 - 04/19/2013 |
Long-Term Effect of In-Utero Exposure to Psychotropic Medications
This one hour session will discuss the currently known risk of malformations, pregnancy outcomes, and neurodevelopment after maternal use of antidepressants, antipsychotic, and traditional mood stabilizers. We will also discuss data types used to determine safety of medications during pregnancy while highlighting the National Register of Antipsychotic Medications in Pregnancy (NRAMP) and the North American Pregnancy Registry. Finally, this presentation will provide tools for patient education to help discuss risk versus benefit of psychotropic medication use in pregnancy. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2010 - 04/19/2013 |
Strategies for the Management of Treatment-Resistant Depression
Treatment resistant depression (TRD) has gotten increased attention given the higher than anticipated incidence demonstrated by the STAR*D trial and the availability of novel pharmacological and other somatic therapies. The difficulties in addressing TRD are magnified by a high incidence of misdiagnosis. The primary sources for misdiagnoses are inadequate treatment, missed diagnoses of bipolarity or psychosis and medical co-morbidities. Approaches to improve differential diagnosis will be discussed. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2010 - 04/19/2013 |
The Role of Folate in Depression and Dementia: The Burden of Vitamin Deficiency
It is well know that folate is essential for the development and normal function of the central nervous system (CNS). This is illustrated by the many cases of in-born errors of folate metabolism which lead to profound deleterious effects in the CNS. The neuropsychiatric complications of folate deficiency from various causes are remarkably similar to those described for vitamin B12 deficiency, but the former is particularly associated with depression and dementia especially in the elderly. Inherited and acquired disorders of folate and B vitamin metabolism are often associated with neurological and psychiatric complications. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/18/2010 - 04/18/2013 |
In a World of Their Own: Diagnosis and Treatment of Autism
Pervasive developmental disorders (PDDs) are neuropsychiatric disorders characterized by social and communication impairments, as well as repetitive interests and activities. The five PDD include Autistic Disorder, Asperger’s Disorders, Rett’s Disorder, Childhood Disintegrative Disorder, and PDD Not Otherwise Specified. Children and adolescents diagnosed with PDDs often suffer from a number of target symptoms that require pharmacologic treatment. Symptoms frequently include hyperactivity and inattention, ritualistic and repetitive behavior, and irritability (aggression, self-injury, tantrums). The purpose of this presentation is to review the diagnosis and treatment of PDDs. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/18/2010 - 04/18/2013 |
New Drugs and Formulations in Psychiatry: Critical Analysis in Formulary Decision-Making
Potential additions to health system formularies are reviewed for safety, efficacy, therapeutic need, and cost. Formularies in mental health have separate issues that must be considered. Clinical decision-making without knowledge from well-designed, controlled, randomized trials with adequate sample size, can incorrectly estimate the efficacy and safety risks associated with specific drug therapy. The practice of evidence-based medicine (EBM) involves integrating clinical expertise with the best available evidence from systematic research. |
2.0 |
Non-member rate: $50.00Member rate: $40.00, login |
| 04/20/2009 - 04/20/2012 |
Adult ADHD: Beyond Childhood
Attention Deficit Hyperactivity Disorder is a common neuropsychiatric condition impacting 4.4% of the adult population age 18-44 according to a recent epidemiological survey. As in childhood, the condition is often marked by challenges with attention, organization and forgetfulness, although adults who were hyperactive as children often grow out of physical hyperactivity. There is evidence that ADHD is associated with poorer outcomes in domestic and occupational endeavors, as well as higher rates of motor vehicle accidents. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2009 - 04/20/2012 |
Cortical Development in Attention-Deficit/Hyperactivity Disorder and the Impact of Psychostimulants
There have been great advances in understanding the neurobiology of ADHD. While there appears to be some overall reduction in brain volumes in children with ADHD, several richly interconnected brain areas seem to be particularly affected- the prefrontal cortex, the basal ganglia and the cerebellum. In addition recent longitudinal studies suggest that ADHD can be understood in part as due to a delay in cortical maturation. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/22/2009 - 04/22/2012 |
Dosage Formulation Technologies for Antipsychotics: The Edge of the Pharmacokinetic-Pharmacodynamic Interface
Dosage formulation technologies are undergoing a renaissance, spanning nanotechnology, polymer chemistry, aerosolization, and smart skin patches. The development of new dosage formulations of antipsychotic medications, focuses upon modified oral release, ultra-fast acting inhalation, and long-acting injectable therapies. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/22/2009 - 04/22/2012 |
Pharmacogenomics Primer and Update
At the intersection of pharmacology and genetics is pharmacogenetics or pharmacogenomics. This rapidly evolving field is one of the cornerstones of Personalized Medicine, however many health care providers do not feel comfortable with the science behind this field nor with the ambiguity in the data that is currently available to support mainstream integration of this field into practice. Thus, the goal of this presentation is to briefly review some of the genetic principals that underlie the field of pharmacogenomics so that health care providers may feel more comfortable in reviewing this literature and be able to understand how to incorporate this science into their practice. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/21/2009 - 04/21/2012 |
Delirium and its Management: Focus on Anticholinergics
Delirium is a state of acute confusion resulting from a general medical condition that can last from hours to months, often fluctuates in severity and presentation, and may include a variety of psychiatric symptoms. It is particularly common in the elderly and those with pre-existing cognitive impairment or brain injury. Delirium is a predictor of multiple adverse outcomes, including functional and cognitive decline, increased length of hospitalization, and mortality. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/21/2009 - 04/21/2012 |
Dispelling the Myths: Point-Counterpoint Debate on European and US Treatment Guidelines for Bipolar Disorder
Bipolar disorder affects approximately 1% of the worldwide population. Several pharmacologic options are available to treat this condition and treatment guidelines are available to direct treatment. Common treatment guidelines in the United States include the American Psychiatric Association guidelines, the Expert Consensus Guidelines, and the Texas Implementation of Medical Algorithms for Bipolar Disorder treatment algorithm, while European guidelines include the European Collegeof Neuropsychopharmacology (ECNP) Consensus Statement on Bipolar Disorder and the National Institute for Health and Clinical Excellence (NICE) guidelines. |
2.0 |
Non-member rate: $50.00Member rate: $40.00, login |
| 04/21/2009 - 04/21/2012 |
Movement Disorders: Focus on Dystonias and Tremor
Idiopathic dystonia and tremor disorders are movement disorders that are underrecognized or undertreated. Familiarity with the clinical features and available treatments will allow clinicians to better identify and manage patients with dystonia or tremor disorders. This session will utilize video cases as learning tools. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/21/2009 - 04/21/2012 |
Treatment of Alcohol Dependence Complicated by Depression and Anxiety Spectrum Disorders
Psychiatric disorders frequently co-occur with alcohol dependence. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) confirms previous epidemiologic data that bipolar disorder has the highest co-occurrence with alcoholism, followed by major depression, generalized anxiety disorder, and social anxiety. Although these disorders frequently co-occur, there are few studies evaluating the treatment of these comorbid conditions. The studies that are available typically focus on the treatment of the underlying psychiatric disorder. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2009 - 04/20/2012 |
Fibromyalgia: An Update on Diagnosis and Treatment Strategies
Fibromyalgia is a widespread chronic pain syndrome characterized by diffuse musculoskeletal achiness, stiffness, and exaggerated tenderness. Current view of the condition indicates that it is a huge continuum of pain and somatic syndromes. It is believed that increase sensitization of the central nervous system to sensory modalities results in the development of many of the symptoms of fibromyalgia. The etiology of fibromyalgia is currently unknown but research is accumulating that indicates that it is most likely multifactorial. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2009 - 04/20/2012 |
Management of Depression in Post-stroke Patients
Although the prevalence of PSD depends upon whether the patients are examined in community settings or acute hospitals, the mean prevalence of major depressive disorder based on pooled data from the world’s literature is 20% during acute poststroke period for major depression and 19% for minor depression. The diagnosis of depression is based on DSM-IV criteria for major or minor depression. There is relatively little effect of physical illness on the manifestations of depressive symptoms. The major risk factors for developing poststroke depression include severity of impairment in activities of daily living, in cognitive function and in social support. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/20/2009 - 04/20/2012 |
Non-Pharmacological Interventions for Schizophrenia
While there is no doubt that medication treatments have demonstrated efficacy for improving clinical symptoms and decreasing rates of relapse for individuals with schizophrenia, many aspects of the illness have not responded or have only partially responded to pharmacotherapy. Multiple psychosocial treatments have been pursued to address these needs. This presentation will focus on two primary types of treatment: Cognitive Behavior Therapy (CBT) and Cognitive Rehabilitation. CBT is designed to decrease the frequency, severity, and the impact on functional outcome of positive symptoms that persist despite adequate medication treatment. |
1.0 |
Non-member rate: $30.00Member rate: $25.00, login |
| 04/19/2009 - 04/19/2012 |
Antidepressants and Suicide Risk in Children and Adults: Using Evidence to Separate Fact from Fiction
Suicide is considered rare in non-depressed individuals but it occurs in between 5 and 15% of those suffering from depression. The Columbia Suicide Severity Rating Scale (C-SSRS) is recommended for assessing an individual patient’s suicide risk. Suicide risk factors in children, adolescents and adults include untreated depression, psychosis, access to firearms. Additional factors that increase suicide risk in children and adolescents include maternal depression, witnessing suicide attempts or sexual abuse or experiencing sexual abuse or trauma themselves. Cyber-bullying is becoming more recognized as a contributing factor to suicide in youth. |
2.0 |
Non-member rate: $30.00Member rate: $25.00, login |